Enovis(ENOV) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported fourth quarter sales of $576 million, reflecting a 3% increase year-over-year on a reported basis and 2% organic growth [12] - For the full year, sales reached $2.2 billion, representing a 7% reported growth, with organic growth of 6% [12][13] - Adjusted gross margins improved to 61%, an increase of 170 basis points, while adjusted EBITDA margin remained flat at 17.9% [13][17] - The company returned to positive free cash flow of $20 million in 2025, with a free cash flow conversion of 10% [8][17] Business Line Data and Key Metrics Changes - Organic revenue growth was 6%, with Recon achieving 8% organic growth, while Prevention and Recovery (PNR) grew 4% [7][12] - In the fourth quarter, Recon grew 3% organically, while PNR was flat [8] - U.S. Recon experienced 6% organic growth in 2025, driven by double-digit growth in extremities [8][9] - Internationally, Recon grew 10% organically, with high single-digit growth in hips and knees [9] Market Data and Key Metrics Changes - The market for Prevention and Recovery is believed to be growing closer to 2%, while the company achieved 4% organic growth in this segment [7] - The company noted that the fourth quarter had four fewer selling days than the prior year, impacting organic growth by 400 basis points [8] Company Strategy and Development Direction - The company is focused on three key priorities: commercial execution, operational excellence, and financial discipline [5] - The "One Enovis" operating mindset aims to improve performance and standardize commercial processes across the organization [6] - The company plans to continue driving innovation, with a robust pipeline of new product introductions planned for the next 24 months [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's long-term plans and positive trajectory despite a dynamic operating environment [14] - The company expects 2026 to be another year of strong execution, with revenue guidance in the range of $2.31 billion to $2.37 billion [18] - Adjusted EBITDA is expected to improve by 50 basis points compared to the prior year, with a focus on driving gross margin improvements [19] Other Important Information - The company recorded a non-cash technical impairment of goodwill of $501 million, which does not impact liquidity or future operations [14] - The company is targeting a free cash flow conversion of 25% or more in 2026, with a pathway to 70%-80% in the future [25][33] Q&A Session Summary Question: Free cash flow conversion improvements - Management highlighted operational improvements and reduced integration-related costs as key drivers for the expected increase in free cash flow conversion [24][25] Question: ARVIS growth expectations - Management is excited about the rollout of ARVIS, expecting domestic rollout in the first half and international rollout in the second half of 2026 [27] Question: U.S. hip and knee business performance - Management indicated that the hip and knee expansion, along with ARVIS, could drive growth above the current range [31] Question: Cash flow and 510(k) filings - Management expects continued incremental improvements in cash flow conversion, despite the need for investments related to ARVIS [33] Question: Q4 cadence issues - Management clarified that Q4 performance was impacted by fewer selling days and did not reflect underlying market changes [36] Question: Gross margin sustainability - Management expects gross margins to continue improving due to positive product mix and productivity initiatives [39] Question: Strategic synergies between segments - Management emphasized the importance of collaboration and optimizing investments across business units to exploit synergies [71] Question: Portfolio shaping and divestitures - Management acknowledged the need for SKU rationalization and portfolio shaping to enhance growth and margin profiles [87]